Acrivon Therapeutics, Inc. ("Acrivon” or "Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage precision medicine company ...

Ladies and gentlemen, thank you for joining us today. Welcome to Compugen's Third Quarter 2024 Results Conference Call. At ...

A team of researchers have applied a novel blood test that can detect early signs of potentially fatal lung damage in cancer ...

Biotheus’ antibody drug targets PD-L1 and VEGF, a design that’s high on drugmakers’ radars after the success of Summit ...

New results from a pooled analysis of patients with previously treated EGFR-mutated NSCLC in the TROPION-Lung05 and TROPION-Lung01 trials will be featured in a late-breaking presentation at the ...

The initial data we presented at ESMO GI in 2024 just a few months ago from the Cornell study highlights this potential. These results in a tumor type, historically resistant to immunotherapy are ...

Good morning and welcome to Agenus' third quarter 2024 conference call and webcast. All participants will be in a listen-only ...

Researchers demonstrate AI-enhanced MRI's potential in diagnosing endometrial cancer, achieving superior accuracy and ...

Investigators assessed whether intravesical BCG is necessary for patients with high-grade T1 nonmuscle-invasive bladder cancer who have unremarkable histology on the second transurethral resection.

Q3 2024 Earnings Conference Call November 12, 2024 8:00 AM ETCompany ParticipantsBill Anderson - Chairman & CEOWolfgang Nickl ...

In July 2024, Checkpoint announced that the FDA accepted for review the resubmission of its BLA for cosibelimab as a complete response to the complete response letter (“CRL”) issued in December 2023 ...

A general view of the Centers for Disease Control and Prevention (CDC) headquarters in Atlanta, Georgia September 30, 2014. REUTERS/Tami Chappell/File Photo The number of sexually transmitted ...